Zhongzhi Pharmaceutical Holdings Management
Management criteria checks 3/4
Zhongzhi Pharmaceutical Holdings' CEO is Ying Feng Lai, appointed in Mar 2021, has a tenure of 3.75 years. total yearly compensation is CN¥1.39M, comprised of 79% salary and 21% bonuses, including company stock and options. directly owns 0.69% of the company’s shares, worth HK$5.39M. The average tenure of the management team and the board of directors is 3.8 years and 9.5 years respectively.
Key information
Ying Feng Lai
Chief executive officer
CN¥1.4m
Total compensation
| CEO salary percentage | 79.0% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.7% |
| Management average tenure | 3.8yrs |
| Board average tenure | 9.5yrs |
Recent management updates
Recent updates
Little Excitement Around Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Earnings As Shares Take 26% Pounding
Aug 22
Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)
Jun 19Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation
May 10Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03
May 05Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03
Apr 21Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares
Feb 01These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well
May 24Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?
Aug 26Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet
Apr 28These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well
Jun 11Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)
May 06Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues
Apr 21Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?
Mar 29The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More
Mar 05Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?
Feb 15
What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?
Jan 14Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?
Dec 27If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late
Dec 14Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?
Nov 30Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥111m |
| Mar 31 2024 | n/a | n/a | CN¥137m |
| Dec 31 2023 | CN¥1m | CN¥1m | CN¥163m |
| Sep 30 2023 | n/a | n/a | CN¥164m |
| Jun 30 2023 | n/a | n/a | CN¥164m |
| Mar 31 2023 | n/a | n/a | CN¥135m |
| Dec 31 2022 | CN¥1m | CN¥802k | CN¥106m |
| Sep 30 2022 | n/a | n/a | CN¥84m |
| Jun 30 2022 | n/a | n/a | CN¥63m |
| Mar 31 2022 | n/a | n/a | CN¥57m |
| Dec 31 2021 | CN¥1m | CN¥791k | CN¥52m |
| Sep 30 2021 | n/a | n/a | CN¥93m |
| Jun 30 2021 | n/a | n/a | CN¥133m |
| Mar 31 2021 | n/a | n/a | CN¥136m |
| Dec 31 2020 | CN¥1m | CN¥801k | CN¥139m |
| Sep 30 2020 | n/a | n/a | CN¥133m |
| Jun 30 2020 | n/a | n/a | CN¥128m |
| Mar 31 2020 | n/a | n/a | CN¥121m |
| Dec 31 2019 | CN¥986k | CN¥700k | CN¥115m |
| Sep 30 2019 | n/a | n/a | CN¥106m |
| Jun 30 2019 | n/a | n/a | CN¥97m |
| Mar 31 2019 | n/a | n/a | CN¥91m |
| Dec 31 2018 | CN¥603k | CN¥274k | CN¥85m |
Compensation vs Market: Ying Feng's total compensation ($USD189.76K) is about average for companies of similar size in the Hong Kong market ($USD230.70K).
Compensation vs Earnings: Ying Feng's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Ying Feng Lai (32 yo)
3.8yrs
Tenure
CN¥1,385,000
Compensation
Mr. Ying Feng Lai has been Executive Director of Zhongzhi Pharmaceutical Holdings Ltd since May 14, 2018 and serves as its Chief Executive since March 24, 2021. Mr. Lai joined the Group since April 2014 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.9yrs | CN¥1.92m | 60.33% HK$ 468.9m | |
| Chief Executive & Executive Director | 3.8yrs | CN¥1.39m | 0.69% HK$ 5.4m | |
| CFO & Executive Director | 3.8yrs | CN¥1.16m | no data | |
| Deputy GM & Executive Director | 3.8yrs | CN¥1.36m | 0.38% HK$ 2.9m | |
| Company Secretary | 7.6yrs | no data | no data |
3.8yrs
Average Tenure
42yo
Average Age
Experienced Management: 3737's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.9yrs | CN¥1.92m | 60.33% HK$ 468.9m | |
| Chief Executive & Executive Director | 6.6yrs | CN¥1.39m | 0.69% HK$ 5.4m | |
| CFO & Executive Director | 2.8yrs | CN¥1.16m | no data | |
| Deputy GM & Executive Director | 9.9yrs | CN¥1.36m | 0.38% HK$ 2.9m | |
| Independent Non-Executive Director | 9.5yrs | CN¥162.00k | no data | |
| Non-Executive Director | 10.3yrs | CN¥270.00k | 4.89% HK$ 38.0m | |
| Independent Non-Executive Director | 9.5yrs | CN¥162.00k | no data | |
| Independent Non-Executive Director | 9.5yrs | CN¥162.00k | no data |
9.5yrs
Average Tenure
56yo
Average Age
Experienced Board: 3737's board of directors are considered experienced (9.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 11:39 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhongzhi Pharmaceutical Holdings Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung-yan Chan | ABCI Securities Company Limited |